Company profile
Theravance Biopharma, Inc.
NASDAQ:TBPHBiotechnology: Pharmaceutical Preparations
Drug pipeline (7)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TELAVANCIN | approved | — | 0 | — |
| AMPRELOXETINE | phase2 | — | 4 | no active trials |
| CEFILAVANCIN | phase2 | — | 1 | no active trials |
| IZENCITINIB | phase2 | — | 4 | completed, terminated |
| NEZULCITINIB | phase2 | — | 2 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (46)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02663089 | phase1 | completed | 2016-02-08 | 2016-03-17 | Theravance Biopharma | A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects |
| NCT01644240 | phase1 | terminated | 2012-09-01 | 2012-11-01 | Theravance Biopharma | A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects |
| NCT01458340 | phase2 | completed | 2011-12-01 | 2013-10-01 | Theravance Biopharma | A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) |
| NCT00687700 | phase1 | completed | 2008-03-10 | 2008-05-27 | Theravance Biopharma | A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers |
| NCT00674817 | phase2 | completed | 2008-04-01 | 2008-10-01 | Theravance Biopharma | An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs. |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 022407 | NDA | THERAVANCE INC | ||||
Loading… | ||||||